BioMark Diagnostics Inc. (BUX.CN) Research

BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.

Market snapshot

Symbol
BUX.CN
Price
$0.55
Day change
+1.85%
Market cap
$57.8M
P/E ratio
-31.98x
52-week range
0.27-0.64
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • DIAGNOS Inc. (ADK.V)
  • Avicanna Inc. (AVCN.TO)
  • Charlotte's Web Holdings, Inc. (CWEB.TO)
  • Gemina Laboratories Ltd. (GLAB.CN)
  • Izotropic Corporation (IZO.CN)
  • MediPharm Labs Corp. (LABS.TO)
  • Microbix Biosystems Inc. (MBX.TO)
  • Perimeter Medical Imaging AI, Inc. (PINK.V)

Open BioMark Diagnostics Inc. (BUX.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.